999 related articles for article (PubMed ID: 26483045)
41. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
[TBL] [Abstract][Full Text] [Related]
42. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
[TBL] [Abstract][Full Text] [Related]
43. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Song P; Guo L; Li W; Zhang F; Ying J; Gao S
J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
[TBL] [Abstract][Full Text] [Related]
45. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
[TBL] [Abstract][Full Text] [Related]
46. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
47. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
[TBL] [Abstract][Full Text] [Related]
48. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
49. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
Nakamura S; Hayashi K; Imaoka Y; Kitamura Y; Akazawa Y; Tabata K; Groen R; Tsuchiya T; Yamasaki N; Nagayasu T; Fukuoka J
PLoS One; 2017; 12(10):e0186192. PubMed ID: 29049375
[TBL] [Abstract][Full Text] [Related]
50. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
51. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
[TBL] [Abstract][Full Text] [Related]
52. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
53. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
Reiniger L; Téglási V; Pipek O; Rojkó L; Glasz T; Vágvölgyi A; Kovalszky I; Gyulai M; Lohinai Z; Rásó E; Tímár J; Döme B; Szállási Z; Moldvay J
Acta Oncol; 2019 Aug; 58(8):1087-1094. PubMed ID: 31002007
[No Abstract] [Full Text] [Related]
54. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Sumitomo R; Hirai T; Fujita M; Murakami H; Otake Y; Huang CL
Lung Cancer; 2019 Oct; 136():136-144. PubMed ID: 31499335
[TBL] [Abstract][Full Text] [Related]
55. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.
Lacour M; Hiltbrunner S; Lee SY; Soltermann A; Rushing EJ; Soldini D; Weder W; Curioni-Fontecedro A
Clin Lung Cancer; 2019 Sep; 20(5):391-396. PubMed ID: 31262689
[TBL] [Abstract][Full Text] [Related]
57. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
58. Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
Vannitamby A; Hendry S; Irving L; Steinfort D; Bozinovski S
Lung Cancer; 2019 Aug; 134():233-237. PubMed ID: 31319986
[TBL] [Abstract][Full Text] [Related]
59. Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
Tancoš V; Grendár M; Farkašová A; Huťka Z; Kviatkovská Z; Plank L
Klin Onkol; 2020; 33(1):55-65. PubMed ID: 32075390
[TBL] [Abstract][Full Text] [Related]
60. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
Grosu HB; Arriola A; Stewart J; Ma J; Bassett R; Hernandez M; Ost D; Roy-Chowdhuri S
Respirology; 2019 Dec; 24(12):1198-1203. PubMed ID: 31209954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]